Sugi Predict

Sugi Predict / Compounds / SCHEMBL62649

SCHEMBL62649

SCHEMBL62649

COC(=O)c1c(C)nc(Cl)nc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ ALDH1A1 P00352 4/20 0.38
▸ HPGD P15428 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ ACHE P22303 1/20 0.38
▸ PLA2G2A P14555 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37
▸ RELA Q04206 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ ABCG2 Q9UNQ0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31368629 1.00 KMT2A (0.41) KMT2AKDM4EMEN1NPSR1SMN1; SMN2
SCHEMBL31368630 1.00 KMT2A (0.41) KMT2AKDM4EMEN1NPSR1SMN1; SMN2
SCHEMBL21032131 0.90 KDM4E (0.45) KMT2AKDM4EMEN1NPSR1SMN1; SMN2
SCHEMBL11481688 0.88 NPSR1 (0.46) KMT2AKDM4EMEN1NPSR1SMN1; SMN2
SCHEMBL61643 0.81 KDM4E (0.40) KMT2AKDM4EMEN1NPSR1SMN1; SMN2
SCHEMBL29635248 0.81 KDM4E (0.49) KMT2AKDM4EMEN1NPSR1SMN1; SMN2
SCHEMBL10995189 0.81 KDM4E (0.49) KMT2AKDM4EMEN1NPSR1SMN1; SMN2
SCHEMBL22712475 0.81 ALDH1A1 (0.46) KMT2AKDM4EMEN1NPSR1SMN1; SMN2
SCHEMBL62780 0.81 KDM4E (0.40) KMT2AKDM4EMEN1NPSR1SMN1; SMN2
SCHEMBL27192993 0.81 NPSR1 (0.40) KMT2AKDM4EMEN1NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106496128-A The synthetic method of medical intermediate 2,4 dichloro 6 methylpyrimidine 5 carboxylate methyl esters 无锡乾浩生物医药有限公司 2017-03-15 — — CN claimed
CN-122074043-A Combination therapy with KRAS modulators 光达治疗公司 2026-05-22 — — CN disclosed
US-12624052-B2 KRAS modulators and uses thereof QUANTA THERAPEUTICS, INC. (US) 2026-05-12 — — US disclosed
EP-4583867-A2 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE Latigo Biotherapeutics, Inc. (US) 2025-07-16 — — EP disclosed
US-20250195524-A1 PYRIMIDO-PYRIDAZINONE COMPOUND AS TOLL-LIKE RECEPTOR AGONIST SHANGHAI VISONPHARMA CO., LTD. (CN) 2025-06-19 — — US disclosed
US-20250154109-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC 2025-05-15 — — US disclosed
WO-2025096490-A1 UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-05-08 — — WO disclosed
EP-4547336-A1 USP1 INHIBITORS AND USES THEREOF Zentaur Therapeutics USA Inc. (US) 2025-05-07 — — EP disclosed
CN-119836421-A USP1 inhibitors and uses thereof 森韬医药美国公司 2025-04-15 — — CN disclosed
US-20250059183-A1 PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST SHANGHAI VISONPHARMA CO., LTD. (CN) 2025-02-20 — — US disclosed
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2010-01-28 — — US disclosed
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2010-01-28 — — US disclosed
EP-2143724-A1 NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES Kissei Pharmaceutical Co., Ltd. (JP) 2010-01-13 — — EP disclosed
EP-1745033-A4 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES NEUROGEN CORP (US) 2009-08-26 — — EP disclosed
US-7482350-B2 4,5-disubstituted-2-aryl pyrimidines NEUROGEN CORPORATION (US) 2009-01-27 — — US disclosed
US-7482350-B2 4,5-disubstituted-2-aryl pyrimidines NEUROGEN CORPORATION (US) 2009-01-27 — — US disclosed
US-7482350-B2 4,5-disubstituted-2-aryl pyrimidines NEUROGEN CORPORATION (US) 2009-01-27 — — US disclosed
EP-1745033-A2 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES NEUROGEN CORPORATION (US) 2007-01-24 — — EP disclosed
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2005-12-15 — — US disclosed
WO-2005110416-A2 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES NEUROGEN CORPORATION (US) 2005-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154109-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE SCN8A, TRPV1, SCNN1A KMT2A 2864/4885KDM4E 3364/4885MEN1 2869/4885
US-20250195524-A1 PYRIMIDO-PYRIDAZINONE COMPOUND AS TOLL-LIKE RECEPTOR AGONIST TLR8, TLR7, TLR1 KMT2A 2718/4885KDM4E 3295/4885MEN1 2708/4885
US-20050277654-A1 4,5-Disubstituted-2-aryl pyrimidines C5AR2, C3AR1, C5AR1 KMT2A 3716/4885KDM4E 2238/4885MEN1 4414/4885
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines C5AR2, C5AR1, C3AR1 KMT2A 3586/4885KDM4E 2149/4885MEN1 4455/4885
US-12624052-B2 KRAS modulators and uses thereof KRAS, NRAS, HRAS KMT2A 2918/4885KDM4E 4532/4885MEN1 1379/4885
US-20250059183-A1 PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST TLR7, TLR8, TLR1 KMT2A 2409/4885KDM4E 2160/4885MEN1 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.